



**Office of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**May 8, 2007 6:30 – 9:00 p.m.**

- 1. Executive Session** **6:30 - 7:00**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**  
(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:25**
  - Clinical Programs Update
  - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:25 - 7:35**
  - Methadone
  - Long Acting Narcotics
  - Capital® w/codeine
  - Ophthalmics: Wetting Agents
- 6. Clinical Update: New Drug Reviews** **7:35 - 8:05**  
(Public comment prior to Board action)
  - Duetact® (pioglitazone/glimepiride) - Abbreviated
  - Januvia® (sitagliptin) / Janumet® (sitagliptin/metformin)
  - Forteo® (teriparatide)
  - Fentora® (fentanyl buccal tablet)
  - Marinol® (dronabinol)
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **8:05 – 8:25**  
(Public comment prior to Board action)
  - Anti-diabetics: Oral
  - Antiemetics: Other
  - COX-II Inhibitors (Quantity Limits)
  - Insulin: Injectable (Levemir® pen)
  - Sedative/Hypnotics: Non-Benzodiazepine
  - Urinary Antispasmodics
- 8. Drug Classes – New** **8:25 – 8:30**  
(Public comment prior to Board action)
  - Saliva Stimulants

<b>9. Miscellaneous</b>	<b>8:30 - 8:40</b>
▪ Compounded Medications	
<b>10. RetroDUR</b>	<b>8:40 - 8:50</b>
▪ Acetaminophen – Daily Dosing Exceeding 4 grams/day	
<b>11. Updated New-to-Market Drug Monitoring Log</b>	<b>8:50 - 8:55</b>
<b>12. Adjourn</b>	<b>9:00</b>